Fiche publication
Date publication
décembre 2025
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr NARDIN Charlée
Tous les auteurs :
de Givry AC, Manchon P, Veyri M, Delyon J, Malissen N, Gaudy-Marqueste C, Zehou O, Jannic A, Gérard E, Kramkimel N, Longvert C, Maubec E, Boileau M, Stoebner PE, Montaudié H, Quéreux G, L'Orphelin JM, Poirier E, Girard C, Nardin C, Mortier L, Ferré VM, Descamps V, Spano JP, Laouenan C, Ghosn J, Lebbé C, Brunet Possenti F
Lien Pubmed
Résumé
People living with HIV (PWH) have an increased risk of developing aggressive skin cancers, yet they have been largely excluded from immune checkpoint inhibitor (ICI) trials. Consequently, evidence on the safety and efficacy of ICIs in this population remains scarce, particularly for the nivolumab plus ipilimumab (NIVO+IPI) combination.
Mots clés
HIV, immune checkpoint inhibitors, immune-related adverse events, melanoma, non-melanoma skin cancer, safety
Référence
Oncologist. 2025 12 15;:
